FMR LLC cut its stake in shares of Atara Biotherapeutics Inc (NASDAQ:ATRA) by 21.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,782,447 shares of the biotechnology company’s stock after selling 751,956 shares during the period. FMR LLC owned 9.64% of Atara Biotherapeutics worth $39,512,000 at the end of the most recent quarter.
Other institutional investors also recently made changes to their positions in the company. Creative Planning acquired a new position in Atara Biotherapeutics during the third quarter worth approximately $213,000. BlackRock Inc. increased its stake in shares of Atara Biotherapeutics by 108.1% in the third quarter. BlackRock Inc. now owns 12,697 shares of the biotechnology company’s stock valued at $272,000 after buying an additional 6,597 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of Atara Biotherapeutics by 37.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 21,797 shares of the biotechnology company’s stock valued at $310,000 after buying an additional 5,883 shares during the period. Alps Advisors Inc. bought a new stake in shares of Atara Biotherapeutics during the third quarter valued at about $786,000. Finally, Teachers Advisors LLC increased its stake in shares of Atara Biotherapeutics by 27.4% in the third quarter. Teachers Advisors LLC now owns 130,251 shares of the biotechnology company’s stock valued at $2,786,000 after buying an additional 28,000 shares during the period. Institutional investors own 77.48% of the company’s stock.
Shares of Atara Biotherapeutics Inc (NASDAQ:ATRA) traded down 10.714% during mid-day trading on Friday, hitting $16.875. 718,788 shares of the company traded hands. Atara Biotherapeutics Inc has a 1-year low of $12.45 and a 1-year high of $25.73. The firm’s 50 day moving average price is $19.06 and its 200-day moving average price is $16.90. The stock’s market capitalization is $490.88 million.
Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings results on Thursday, March 9th. The biotechnology company reported ($0.63) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.98) by $0.35. On average, equities research analysts forecast that Atara Biotherapeutics Inc will post ($3.62) EPS for the current year.
TRADEMARK VIOLATION NOTICE: This news story was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this news story on another domain, it was stolen and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://sportsperspectives.com/2017/04/21/fmr-llc-has-39512000-stake-in-atara-biotherapeutics-inc-atra-updated-updated.html.
Several equities research analysts have issued reports on ATRA shares. Citigroup Inc set a $10.00 price objective on shares of Atara Biotherapeutics and gave the stock a “sell” rating in a research report on Thursday, March 16th. Zacks Investment Research upgraded shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, January 4th. Finally, Canaccord Genuity set a $47.00 target price on shares of Atara Biotherapeutics and gave the stock a “buy” rating in a research note on Wednesday, January 18th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $24.00.
In other news, EVP Christopher Haqq sold 6,000 shares of the stock in a transaction on Monday, April 17th. The shares were sold at an average price of $17.28, for a total value of $103,680.00. Following the sale, the executive vice president now owns 380,855 shares of the company’s stock, valued at $6,581,174.40. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Mitchall G. Clark sold 3,059 shares of the company’s stock in a transaction dated Thursday, February 16th. The stock was sold at an average price of $15.96, for a total transaction of $48,821.64. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 151,195 shares of company stock worth $2,738,542. 16.10% of the stock is owned by insiders.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
Receive News & Ratings for Atara Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.